Razuprotafib Uses, Dosage, Side Effects and more
Razuprotafib, also known as AKB-9778, is a small-molecule inhibitor restoring Tie2 activation by inhibiting VE-PTP. In investigations against diabetes and COVID-19, razuprotafib is self-administered by patients through subcutaneous injection.
| Attribute | Details |
|---|---|
| Trade Name | Razuprotafib |
| Generic | Razuprotafib |
| Razuprotafib Other Names | Razuprotafib |
| Type | |
| Formula | C26H26N4O6S3 |
| Weight | Average: 586.7 Monoisotopic: 586.101448095 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
How Razuprotafib works
Razuprotafib inhibits VE-PTP (a negative regulator of Tie2 in diseased blood vessels) by binding and inhibiting the intracellular catalytic domain of VE-PTP that inactivates Tie2. This in turn allows razuprotafib to restore Tie2 activation to allow for enhancement of endothelial function and stabilization of blood vessels. Razuprotafib is being investigated against diabetic vascular complications and acute respiratory distress syndrome (ARDS) in COVID-19.
